Alcon (ALC) Q4 2024 earnings summary

Executive summary

• 2024 net sales reached $9.8 billion, up 5–6% year-over-year, with both Surgical and Vision Care segments contributing to growth.

• Core diluted EPS increased 16% to $3.05, and core operating income rose 10% to $2.0 billion.

• Free cash flow more than doubled to $1.6 billion, supporting strategic investments and operational efficiency.

• Major product launches and organizational realignment enhanced innovation and speed to market.

• Operating income increased 36% to $1.4 billion, aided by a $57 million gain from a China product rights divestment.

Financial highlights

• Q4 2024 sales were $2.5 billion, up 6% year-over-year, with core operating margin at 20.1% and core diluted EPS at $0.72 (+3% YoY).

• FY24 cash from operations totaled $2.1 billion; free cash flow was $1.6 billion, more than doubling from $0.7 billion in FY23.

• Capex for FY24 was $473 million, mainly for expanding contact lens manufacturing.

• Cash and cash equivalents at year-end were $1.7–1.8 billion; total debt stood at $4.6 billion.

• EBITDA reached $2.6 billion, up from $2.3 billion year-over-year.

Outlook and guidance

• 2025 revenue expected between $10.2–$10.4 billion, with 6–8% constant currency growth and 2 points FX headwind.

• Core operating margin guidance: 21–22%, with margin expansion weighted to the second half due to new product launches.

• Core diluted EPS guidance: $3.15–$3.25 (8–11% constant currency growth), with $0.15 FX pressure mostly in H1.

• Dividend increase to CHF 0.28/share proposed; $750 million share repurchase program authorized.

• R&D investment targeted at 8–10% of sales, with increased focus on innovation.